IN2012DN03127A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03127A
IN2012DN03127A IN3127DEN2012A IN2012DN03127A IN 2012DN03127 A IN2012DN03127 A IN 2012DN03127A IN 3127DEN2012 A IN3127DEN2012 A IN 3127DEN2012A IN 2012DN03127 A IN2012DN03127 A IN 2012DN03127A
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Zhanggui Wu
Original Assignee
Zhanggui Wu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhanggui Wu filed Critical Zhanggui Wu
Publication of IN2012DN03127A publication Critical patent/IN2012DN03127A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN3127DEN2012 2009-09-18 2012-04-11 IN2012DN03127A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24354909P 2009-09-18 2009-09-18
PCT/US2010/049199 WO2011035077A1 (en) 2009-09-18 2010-09-17 Novel compounds and therapeutic use thereof for protein kinase inhibition

Publications (1)

Publication Number Publication Date
IN2012DN03127A true IN2012DN03127A (de) 2015-09-18

Family

ID=43759014

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3127DEN2012 IN2012DN03127A (de) 2009-09-18 2012-04-11

Country Status (12)

Country Link
US (2) US8815863B2 (de)
EP (2) EP2477496B1 (de)
JP (1) JP6155026B2 (de)
CN (2) CN102711475B (de)
AU (2) AU2010295492B2 (de)
CA (1) CA2774367C (de)
ES (2) ES2587509T3 (de)
IN (1) IN2012DN03127A (de)
MX (1) MX2012003286A (de)
NZ (1) NZ599453A (de)
RU (1) RU2012109220A (de)
WO (1) WO2011035077A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2587509T3 (es) * 2009-09-18 2016-10-25 Zhanggui Wu Derivados de tieno[2,3-d]piridazina y uso terapéutico de los mismos para la inhibición de proteína cinasa
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
CN115038439B (zh) * 2020-01-07 2026-04-21 上海华禹生物科技有限公司 使用chk抑制剂的癌症联合疗法
WO2021177728A1 (ko) * 2020-03-04 2021-09-10 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 난소암 예방, 개선 또는 치료 용도
EP4137494A4 (de) * 2020-04-17 2024-03-13 ZheJiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory Kristallform einer thiofuranpyridazinverbindung, herstellungsverfahren dafür und anwendung davon
CN116332960A (zh) * 2021-12-23 2023-06-27 上海优理惠生医药有限公司 一种哒嗪类化合物、其药物组合物及应用
CN117263950A (zh) * 2022-06-13 2023-12-22 上海优理惠生医药有限公司 一种哒嗪类化合物、其药物组合物及应用
JP2024026975A (ja) * 2022-08-16 2024-02-29 富士フイルム株式会社 Syk阻害剤および医薬組成物
CN117003736B (zh) * 2023-10-07 2023-12-15 天津匠新致成科技有限公司 3-氨基吡嗪-2-甲酰胺类靶向蛋白水解嵌合体及其制备方法、药物组合物和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028731A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2003029241A1 (en) 2001-10-04 2003-04-10 Smithkline Beecham Corporation Chk1 kinase inhibitors
WO2004041285A1 (en) * 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
ATE501138T1 (de) * 2004-01-05 2011-03-15 Astrazeneca Ab Thiophenderivate als chk-1-inhibitoren
CA2563990A1 (en) 2004-05-04 2005-11-10 Sharada Shenvi Labadie Thienopyridazines as ikk inhibitors
AU2005238180A1 (en) * 2004-05-04 2005-11-10 F. Hoffmann-La Roche Ag Thienopyridines as IKK inhibitors
CN101189243A (zh) * 2005-04-06 2008-05-28 阿斯利康(瑞典)有限公司 取代的杂环及其作为chk1、pdk1和pak抑制剂的应用
EP1869052A1 (de) * 2005-04-06 2007-12-26 AstraZeneca AB Substituierte heterocyclen und ihre verwendung als chk1-, pdk1- und pak-inhibitoren
WO2007124181A2 (en) * 2006-04-21 2007-11-01 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
KR20090027754A (ko) 2006-07-03 2009-03-17 코닌클리케 필립스 일렉트로닉스 엔.브이. 신선도 표시기를 갖는 음료 분배장치
CN101481380B (zh) * 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
ES2587509T3 (es) * 2009-09-18 2016-10-25 Zhanggui Wu Derivados de tieno[2,3-d]piridazina y uso terapéutico de los mismos para la inhibición de proteína cinasa

Also Published As

Publication number Publication date
CA2774367A1 (en) 2011-03-24
US20120232082A1 (en) 2012-09-13
CN104628741A (zh) 2015-05-20
EP2477496A4 (de) 2013-02-27
US9487539B2 (en) 2016-11-08
AU2010295492B2 (en) 2016-05-05
AU2010295492A1 (en) 2012-05-03
AU2016204867B2 (en) 2017-02-16
BR112012006062A2 (pt) 2015-09-08
ES2481791T3 (es) 2014-07-31
HK1170908A1 (en) 2013-03-15
CN102711475A (zh) 2012-10-03
AU2016204867A1 (en) 2016-07-28
RU2012109220A (ru) 2013-10-27
EP2826780A1 (de) 2015-01-21
JP2013505254A (ja) 2013-02-14
EP2826780B1 (de) 2016-06-01
ES2587509T3 (es) 2016-10-25
US8815863B2 (en) 2014-08-26
US20150072987A1 (en) 2015-03-12
WO2011035077A1 (en) 2011-03-24
CN102711475B (zh) 2015-01-28
EP2477496B1 (de) 2014-04-16
CA2774367C (en) 2018-07-10
NZ599453A (en) 2014-03-28
JP6155026B2 (ja) 2017-06-28
EP2477496A1 (de) 2012-07-25
MX2012003286A (es) 2012-06-19

Similar Documents

Publication Publication Date Title
BE2015C040I2 (de)
BRPI0925311A2 (de)
BRPI0924307A2 (de)
BRPI1009599A2 (de)
BR112012012396A2 (de)
BR122021004633A2 (de)
BR112012000665A2 (de)
BR112012012487A2 (de)
BR122017024704A2 (de)
BR112012003853A2 (de)
BR112012012080A2 (de)
BRPI0924534A2 (de)
BR112012001263A2 (de)
BR122019005883A2 (de)
BRPI1004942A2 (de)
BR112012014856A2 (de)
BR112012000159A2 (de)
BR112012002627A2 (de)
BR112012000255A2 (de)
BR112012005951A2 (de)
BR112012000156A2 (de)
BR122017013721A2 (de)
BRPI0925022A2 (de)
BRPI0924617A2 (de)
BR112012016234A2 (de)